AU2006273928B2 - Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use - Google Patents

Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use Download PDF

Info

Publication number
AU2006273928B2
AU2006273928B2 AU2006273928A AU2006273928A AU2006273928B2 AU 2006273928 B2 AU2006273928 B2 AU 2006273928B2 AU 2006273928 A AU2006273928 A AU 2006273928A AU 2006273928 A AU2006273928 A AU 2006273928A AU 2006273928 B2 AU2006273928 B2 AU 2006273928B2
Authority
AU
Australia
Prior art keywords
cell
marker
ephrin
ligand
eph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006273928A
Other languages
English (en)
Other versions
AU2006273928A1 (en
Inventor
Philippe Foubert
Sophie Le Ricousse-Roussanne
Jean-Sebastien Silvestre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Original Assignee
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Diderot Paris 7, IVS Institut des Vaisseaux et du Sang filed Critical Universite Paris Diderot Paris 7
Publication of AU2006273928A1 publication Critical patent/AU2006273928A1/en
Application granted granted Critical
Publication of AU2006273928B2 publication Critical patent/AU2006273928B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2006273928A 2005-07-27 2006-07-27 Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use Ceased AU2006273928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0508029 2005-07-27
FR0508029A FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
PCT/FR2006/001837 WO2007012764A2 (fr) 2005-07-27 2006-07-27 Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique

Publications (2)

Publication Number Publication Date
AU2006273928A1 AU2006273928A1 (en) 2007-02-01
AU2006273928B2 true AU2006273928B2 (en) 2012-02-16

Family

ID=36353668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006273928A Ceased AU2006273928B2 (en) 2005-07-27 2006-07-27 Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use

Country Status (11)

Country Link
US (1) US8338169B2 (enExample)
EP (1) EP1913130B1 (enExample)
JP (4) JP5755829B2 (enExample)
CN (1) CN101273123B (enExample)
AU (1) AU2006273928B2 (enExample)
CA (1) CA2616712C (enExample)
DK (1) DK1913130T3 (enExample)
ES (1) ES2565675T3 (enExample)
FR (1) FR2889200B1 (enExample)
IL (1) IL188938A (enExample)
WO (1) WO2007012764A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
AU2008223817A1 (en) 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
WO2000031124A2 (en) 1998-11-20 2000-06-02 Mount Sinai Hospital Peptides that modulate the interaction of b class ephrins and pdz domains
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
AU2002311792A1 (en) 2001-03-30 2002-10-15 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
US20050049194A1 (en) 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
AU2003232457A1 (en) 2002-05-29 2003-12-19 Curagen Corporation Compositions and methods of use for an ephrin rreceptor
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Maekawa et al, Arteriosclerosis Thrombosis Vascular Biology (2003), Vol 23, No 11 pages 2008-2014. *

Also Published As

Publication number Publication date
WO2007012764A2 (fr) 2007-02-01
JP6235639B2 (ja) 2017-11-22
ES2565675T3 (es) 2016-04-06
CN101273123B (zh) 2013-06-26
CN101273123A (zh) 2008-09-24
IL188938A0 (en) 2008-04-13
EP1913130B1 (fr) 2015-12-23
JP2017169590A (ja) 2017-09-28
JP5755829B2 (ja) 2015-07-29
IL188938A (en) 2014-09-30
AU2006273928A1 (en) 2007-02-01
JP2009505638A (ja) 2009-02-12
DK1913130T3 (en) 2016-03-29
US8338169B2 (en) 2012-12-25
FR2889200B1 (fr) 2008-01-04
JP5981525B2 (ja) 2016-08-31
FR2889200A1 (fr) 2007-02-02
EP1913130A2 (fr) 2008-04-23
CA2616712A1 (fr) 2007-02-01
JP2016127863A (ja) 2016-07-14
CA2616712C (fr) 2015-11-17
WO2007012764A3 (fr) 2007-05-31
US20090123431A1 (en) 2009-05-14
JP2015061536A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
Won et al. Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient
Lo et al. Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): pilot validation in porcine ischemia-reperfusion model
CN118634339A (zh) 用于细胞疗法的基于靶向性配体-有效负载的药物递送
KR101265492B1 (ko) 줄기세포를 혈관세포로 분화시키는 방법 및 이를 이용한 생체 내 혈관신생 유도
Maxwell et al. Stimulation of glucose analogue uptake by cerebral microvessel endothelial cells by a product released by astrocytes
ES2534724T3 (es) Células madre hematopoyéticas adecuadas para el trasplante, su preparación y composiciones farmacéuticas que las comprenden
JP6235639B2 (ja) Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途
JPH03503167A (ja) 部位指定血管形成素子とその使用法
EP0535148A1 (en) Stimulation of bone marrow stromal and progenitor cells
Eun et al. Overexpression of phosphoinositide-3-kinase class II alpha enhances mesenchymal stem cell survival in infarcted myocardium
Klimovich et al. Mechanisms of participation of the urokinase receptor in directed axonal growth
US20100068145A1 (en) Bispecific fusion protein having therapeutic and diagnostic potential
JP2014039560A (ja) 脈管形成組成物
Rosengart et al. Heparin-binding growth factor-I (endothelial cell growth factor) binds to endothelium in vivo
ES2366701T3 (es) Técnicas in vitro para su uso con células madre.
US20240316115A1 (en) Method for producing vascular endothelial growth factor (vegf)- highly expressing pericyte-like cell
US20240335480A1 (en) Vascular endothelial growth factor (vegf)-highly expressing pericyte-like cell
KR20230009409A (ko) 피브리노겐 단편 및 라미닌 단편을 포함하는 융합단백질 및 그 이용
Kang et al. Thermostable bFGF Improves Cell Lifespan by Enhancing Cell Activity in the Long-Term Culture of Human Orbicularis Oculi Stem Cells
WO2002044345A1 (en) Methods and products for manipulating hematopoietic stem cells
Miller et al. Notch Signaling at Later Stages of NK Cell

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired